Navigation Links
BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
Date:1/28/2009

NOVATO, Calif., Jan. 28 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 18, at 5:00 p.m. ET (23:00 CET) to discuss fourth quarter and full year 2008 financial results.

    U.S. / Canada Dial-in Number:  866.700.6293
    International Dial-in Number:  617.213.8835
    Participant Code: 35749059
    Replay Dial-in Number: 888.286.8010
    Replay International Dial-in Number: 617.801.6888
    Replay Code: 73992450

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

    Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

     Contacts:

     Investors                         Media
     Eugenia Shen                      Susan Berg
     BioMarin Pharmaceutical Inc.      BioMarin Pharmaceutical Inc.
     (415) 506-6570                    (415) 506-6594

'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Related biology technology :

1. BioMarin to Present at the Piper Jaffray Healthcare Conference
2. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
3. BioMarin to Present at the Credit Suisse Healthcare Conference
4. BioMarin Announces Third Quarter 2008 Financial Results
5. BioMarin Corrects Information Included in Bloomberg Article
6. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
7. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
8. BioMarin to Present at the Citi Biotech Day
9. BioMarin Announces Roll-Out of National PKU Registry
10. BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
11. BioMarin to Present at the Collins Stewart Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... Westlake Village, CA (PRWEB) , ... August 17, ... ... biopsy technology for cancer research and personalized medicine, today announced the launch of ... in Kansas City, Missouri. The study’s goal is to evaluate the potential for ...
(Date:8/16/2017)... ... ... While art and science are often thought of as two completely separate ... A Mesh Is Also a Snare, a group exhibition presented by the Philadelphia-based artist ... (EKG) on August 17 and run through September 30. An opening reception will be ...
(Date:8/16/2017)... BOSTON and OXFORD, England , ... -based consortium for biotech executive search and leadership development, ... and Healthcare sectors, have created an exclusive alliance that enables ... "For our clients here ... collaboration provides unparalleled access to a diverse population of leadership ...
(Date:8/15/2017)... PA (PRWEB) , ... August 15, 2017 , ... ... one of the largest Asian exhibitions for analytical and scientific instruments. This year’s ... will be “New Approaches in Mass Spectrometry for Bioanalytical Applications.” This dynamic presentation ...
Breaking Biology Technology:
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017 /PRNewswire/ ... leader in dairy research, today announced a new collaboration ... reduce the chances that the global milk supply is ... dairy project, Cornell University has become the newest academic ... Supply Chain, a food safety initiative that includes IBM ...
(Date:5/6/2017)... 5, 2017 RAM Group , ... new breakthrough in biometric authentication based on a ... properties to perform biometric authentication. These new sensors are ... created by Ram Group and its partners. This sensor ... supply chains and security. Ram Group is a ...
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
Breaking Biology News(10 mins):